Abstract
Transcutaneous monitoring of CO2, with improved specificity over end-tidal CO2 monitoring, offers meaningful trending to inform clinician decision-making around readiness to wean. Additionally, transcutaneous monitoring allows for noninvasive, reliable continuous metabolic monitoring to serve as an early clinical indicator for at-risk patients.